51372 Barzolvolimab demonstrates safety and clinically meaningful activity as early as two weeks in moderate to severe prurigo nodularis.

Details

Language :

English

ISSN :

01909622

Volume :

91

Issue :

3

Database :

Supplemental Index

Journal :

Journal of the American Academy of Dermatology

Publication Type :

Academic Journal

Accession number :

179275583

Full Text :

https://doi.org/10.1016/j.jaad.2024.07.562